Folate vs. Folic Acid: Why the Form of B9 You Take Before Pregnancy Actually Matters

Neural tube defects — conditions like spina bifida and anencephaly — occur during the first 28 days after conception, often before a woman even knows she's pregnant. Folate is the nutrient most tightly linked to preventing them. But here's what most prenatal advice skips over: not all B9 supplements are the same, and for a significant portion of the population, the most common form — synthetic folic acid — may be processed far less efficiently than the label implies.

This isn't fringe science. It comes down to a single enzyme, a surprisingly common gene variant, and a metabolic bottleneck that most standard supplementation advice still doesn't account for.

What "Folate" Actually Means (and Why the Labels Are Confusing)

Folate is the umbrella term for a family of water-soluble B vitamins found naturally in foods — dark leafy greens, legumes, liver. The form your cells actually use is called 5-methyltetrahydrofolate, or 5-MTHF. This is what circulates in your bloodstream and gets transported into tissues (Pietrzik et al., Clinical Pharmacokinetics, 2010).

Folic acid is different. It's a fully oxidized, synthetic molecule found only in supplements and fortified foods — it does not exist in nature. Folic acid has no direct coenzyme activity. Before your body can use it, it must be chemically reduced through several enzymatic steps to become metabolically active tetrahydrofolate (Pietrzik et al., Clinical Pharmacokinetics, 2010). Folate from food and 5-MTHF supplements bypass most of these conversion steps entirely (Scaglione & Panzavolta, Xenobiotica, 2014).

Why does this matter? Because that conversion process depends heavily on an enzyme called MTHFR — and in a large share of the population, that enzyme doesn't work at full capacity.

The MTHFR Gene: What It Does and How Common Variants Are

MTHFR (methylenetetrahydrofolate reductase) is the enzyme that converts folate into the active 5-MTHF form usable by your cells. It also plays a central role in a process called methylation — the biochemical machinery your body uses to regulate gene expression, build neurotransmitters, and detoxify homocysteine, a potentially harmful amino acid (Araszkiewicz et al., Genes, 2025).

The two most studied variants are C677T (rs1801133) and A1298C (rs1801131). The C677T variant is the one most clinically relevant to folate metabolism and neural tube risk. Carrying one copy (heterozygous) reduces MTHFR enzyme activity moderately; carrying two copies (homozygous TT) can reduce it substantially (Födinger et al., Journal of Nephrology, 2000). When MTHFR activity is impaired, homocysteine accumulates — a condition called hyperhomocysteinemia — because the methylation cycle that would normally clear it slows down (Perry, Bailliere's Best Practice & Research, 1999).

Critically, MTHFR polymorphisms have been associated with neural tube defects in multiple studies, and the relationship between these variants and NTD risk appears to be influenced by dietary folate intake (Molloy et al., Annual Review of Nutrition, 2017). The genetics of NTDs are genuinely complex — many genes and environmental factors interact — but MTHFR remains one of the most studied (Gelineau-van Waes et al., Seminars in Pediatric Neurology, 2001).

Why Folic Acid Alone May Fall Short for Some Women

Here's the metabolic bottleneck. When a woman with reduced MTHFR activity takes standard folic acid, her body struggles to convert it into usable 5-MTHF efficiently. The conversion stalls. Meanwhile, unmetabolized folic acid can accumulate in the bloodstream — a phenomenon with its own potential concerns (Scaglione & Panzavolta, Xenobiotica, 2014).

5-MTHF supplements sidestep this entirely. Because 5-MTHF is already in the biologically active form, it doesn't require MTHFR conversion. Its bioavailability is not affected by metabolic defects caused by MTHFR polymorphisms, and it is well absorbed even when gastrointestinal pH is altered (Scaglione & Panzavolta, Xenobiotica, 2014). Studies comparing L-5-methyltetrahydrofolate and folic acid found that the two compounds have comparable physiological activity and bioavailability at equimolar doses in people with normal MTHFR function — but 5-MTHF has advantages for those with impaired enzyme activity (Pietrzik et al., Clinical Pharmacokinetics, 2010).

There's also a vitamin B12 consideration. High-dose folic acid can mask the hematological signs of B12 deficiency — a risk that is reduced with 5-MTHF (Scaglione & Panzavolta, Xenobiotica, 2014).

Neural Tube Closure: The Timeline That Makes Preconception Supplementation Non-Negotiable

The neural tube — the embryonic structure that becomes the brain and spinal cord — closes between days 21 and 28 after fertilization. That's before most women have missed a period. By the time a pregnancy is confirmed and supplementation begins, the window for preventing NTDs has often already closed (Valentin et al., Annales d'Endocrinologie, 2018).

NTDs affect roughly 0.5 to 2 per 1,000 pregnancies, and folic acid deficiency — absolute or relative — is a recognized predisposing factor (Valentin et al., Annales d'Endocrinologie, 2018). The evidence for periconceptional folate supplementation is strong: randomized controlled trials showed that higher-dose folic acid (4 mg) significantly reduces NTD recurrence, and 0.4 mg/day reduces first occurrence (Valentin et al., Annales d'Endocrinologie, 2018). Folate intake must begin before conception — not after the positive test (Kondo et al., Congenital Anomalies, 2017).

Elevated homocysteine — which rises when folate metabolism is impaired — has also been directly linked to NTD risk. Eskes et al. identified hyperhomocysteinemia as a maternal risk factor, with folate, B6, and B12 supplementation as the intervention to reduce it (Eskes, European Journal of Pediatrics, 1998).

Practical Guidance for Parents and Those Planning Pregnancy

A few concrete points to discuss with your healthcare provider:

Know your MTHFR status — or plan around uncertainty. MTHFR testing is available but not universally recommended as a screening tool. If you have a personal or family history of NTDs, recurrent pregnancy loss, or elevated homocysteine, it's worth asking. Even without testing, choosing a prenatal supplement containing methylfolate (5-MTHF) rather than, or in addition to, folic acid is a reasonable precaution — especially since 5-MTHF appears at least as effective as folic acid in improving folate status in the general population (Pietrzik et al., Clinical Pharmacokinetics, 2010).

Start before conception — ideally 1–3 months prior. Neural tube closure happens in the first four weeks of pregnancy. Waiting until a confirmed pregnancy to start supplementation is too late for NTD prevention (Kondo et al., Congenital Anomalies, 2017).

Food sources still matter. Natural food folate — from lentils, spinach, asparagus, fortified grains — contributes meaningfully to folate status alongside supplements. Mammals cannot synthesize folate endogenously and depend entirely on dietary intake (Scaglione & Panzavolta, Xenobiotica, 2014).

B12 matters too. MTHFR-related methylation problems interact with B12 status. If you're taking higher folate doses, ensure adequate B12 intake — both to support methylation and to avoid masking deficiency (Pietrzik et al., Clinical Pharmacokinetics, 2010).

The label on your supplement bottle says "folic acid" — but that's not the end of the story. For millions of people with MTHFR variants, the form of B9 they take genuinely changes how much of it their body can put to work. It's one of the more actionable pieces of preconception nutrition science we have, and it's worth one conversation with your doctor before you start trying to conceive.

Have questions about prenatal nutrition or genetic variants that affect child development? Browse more evidence-based guides at Avaneuro.

References

Scaglione, F., et al. (2014). Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. https://pubmed.ncbi.nlm.nih.gov/24494987/
Araszkiewicz, A.F., et al. (2025). MTHFR Gene Polymorphisms: A Single Gene with Wide-Ranging Clinical Implications-A Review. Genes. https://pubmed.ncbi.nlm.nih.gov/40282401/
Pietrzik, K., et al. (2010). Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics. https://pubmed.ncbi.nlm.nih.gov/20608755/
Donnelly, J.G. (2001). Folic acid. Critical Reviews in Clinical Laboratory Sciences. https://pubmed.ncbi.nlm.nih.gov/11451208/
Perry, D.J. (1999). Hyperhomocysteinaemia. Bailliere's Best Practice & Research. Clinical Haematology. https://pubmed.ncbi.nlm.nih.gov/10856981/
Valentin, M., et al. (2018). Acid folic and pregnancy: A mandatory supplementation. Annales d'Endocrinologie. https://pubmed.ncbi.nlm.nih.gov/29433770/
Kondo, A., et al. (2017). Neural tube defects: Risk factors and preventive measures. Congenital Anomalies. https://pubmed.ncbi.nlm.nih.gov/28425110/
Gelineau-van Waes, J., et al. (2001). Genetics of neural tube defects. Seminars in Pediatric Neurology. https://pubmed.ncbi.nlm.nih.gov/11575845/
Molloy, A.M., et al. (2017). Genetic Risk Factors for Folate-Responsive Neural Tube Defects. Annual Review of Nutrition. https://pubmed.ncbi.nlm.nih.gov/28628360/
Födinger, M., et al. (2000). Molecular biology of 5,10-methylenetetrahydrofolate reductase. Journal of Nephrology. https://pubmed.ncbi.nlm.nih.gov/10720211/
Eskes, T.K. (1998). Neural tube defects, vitamins and homocysteine. European Journal of Pediatrics. https://pubmed.ncbi.nlm.nih.gov/9587043/